HEALING SURGICAL WOUNDS WITH HUMAN PLASMA
Haemacure is developing human biological products for use during surgery to stop bleeding, seal tissues, and speed healing.
Hub Controls
  • Control Panel Demo
  • Upload Photo
  • Edit Company Profile
  • Add a Link
  • Update Fast Facts
  • Add Management Bios
  • Private Messages
  • Edit Your Profile
Haemacure Corporation > Message
Agoraa

Re: market potential?

Posted by: AGORACOM on April 25, 2008 11:59AM

In response to: market potential? by sparky69

Dear "sparky69"

Thank you for your question.

I refer you to the "Profile" section of this hub. You can click on that tab on the left hand side. Here it answers your question:

*The current worldwide general haemostasis market is estimated at approximately US$675 million and expected to reach US$1.5 billion by 2015. Fibrin sealant use is expected to grow with its increasing acceptance by surgeons, widening fields of use, and an increasing number of surgeries.

We thank you for your question and we continue to encourage constructive dialogue regarding Haemacure.

AGORACOM Investor Relations

Post a Reply

Please login to reply to this message.

Executive Address
Hae-galli-bc
Joseph Galli
CEO
July 07, 2008

A recent interview with the CEO discussing the company's progress

View Broadcast